2. Academic Validation
  3. LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC

  • Nat Commun. 2026 Mar 25. doi: 10.1038/s41467-026-70984-1.
Takumitsu Machida # 1,  Yingbo Gong # 2,  Sayaka Tsukioka 1,  Atsushi Onodera 3 4,  Akitoshi Nakayama 2,  Naoko Hashimoto 2 3 4,  Takahiro Fuchigami 2,  Motoi Nishimura 5,  Tomohiro Ogino 3,  Ryota Kurimoto 2,  Yasufumi Uematsu 6,  Hidemi Suzuki 6,  Hongye Yu 2,  Mingyang Chen 2,  Masataka Yokoyama 2,  Ikki Sakuma 2,  Yuki Taki 2,  Takashi Kono 2 3,  Takashi Miki 7 3,  Shinichiro Motohashi 8,  Yusuke Kawashima 9,  Osamu Ohara 9,  Satoshi Yamashita 1,  Tatsuya Suzuki 1,  Ryo Hatanaka 1,  Yasuo Kodama 1,  Shuichi Ohkubo 10,  Tomoaki Tanaka 11 12
Affiliations

Affiliations

  • 1 Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan.
  • 2 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • 3 Research Institute of Disaster Medicine (RIDM), Chiba University, Chiba, Japan.
  • 4 Institute for Advanced Academic Research, Chiba University, Chiba, Japan.
  • 5 Division of Laboratory Medicine, Clinical Genetics and Proteomics, Chiba University Hospital, Chiba, Japan.
  • 6 Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • 7 Department of Medical Physiology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • 8 Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • 9 Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Japan.
  • 10 Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan. s-ohkubo@taiho.co.jp.
  • 11 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan. tomoaki@restaff.chiba-u.jp.
  • 12 Research Institute of Disaster Medicine (RIDM), Chiba University, Chiba, Japan. tomoaki@restaff.chiba-u.jp.
  • # Contributed equally.
PMID: 41881985 DOI: 10.1038/s41467-026-70984-1
Abstract

Small cell lung Cancer (SCLC) is aggressive with limited treatment options, requiring new therapies. Lysine-specific Histone Demethylase 1 A (LSD1) maintains neuroendocrine state by repressing Notch/TGF-β signaling; their reactivation suppresses proliferation and induces differentiation. However, mechanisms of LSD1 inhibition and chemoresistance remain unclear. Here we developed TAS1440, a histone H3-competitive LSD1 inhibitor, using structure-based engineering to improve specificity and reduce off-target effects. Unlike irreversible inhibitors targeting the flavin adenine dinucleotide site, TAS1440 non-covalently targets the H3-binding pocket to enhance safety and efficacy. TAS1440 suppressed proliferation in INSM1/ASCL1-high SCLC-A cells and induced tumor regression in xenografts. TAS1440 acts through dual mechanisms: inhibiting LSD1 activity and disrupting LSD1-repressive complexes, remodeling histone marks and activating transcription factors INSM1 and SMAD2. These actions reprogram tumor-suppressive TGF-β/Notch signaling, supporting TAS1440 as epigenetic therapy for SCLC. Loss of LSD1 enzymatic activity or INSM1 knockout abrogated TAS1440 effects, defining its mode of action and chemoresistance. These findings support TAS1440 as a next-generation epigenetic therapy candidate for INSM1-high SCLC-A.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z